Alaunos Therapeutics, Inc. Deferred Tax Assets, Gross
Alaunos Therapeutics, Inc. (TCRT) had Deferred Tax Assets, Gross of $213.58 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGross · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Gross $213.58M.
- 2024-12-31: Deferred Tax Assets, Gross $213.28M.
- 2023-12-31: Deferred Tax Assets, Gross $211.03M.
- 2022-12-31: Deferred Tax Assets, Gross $237.31M.
| Period end | Deferred Tax Assets, Gross |
|---|---|
| 2025-12-31 | $213.58M 10-K · filed 2026-03-31 |
| 2024-12-31 | $213.28M 10-K · filed 2026-03-31 |
| 2023-12-31 | $211.03M 10-K · filed 2025-03-31 |
| 2022-12-31 | $237.31M 10-K · filed 2024-04-01 |
| 2021-12-31 | $231.20M 10-K · filed 2023-03-07 |
| 2020-12-31 | $216.70M 10-K · filed 2022-03-30 |
| 2019-12-31 | $197.30M 10-K · filed 2021-03-01 |
| 2018-12-31 | $181.29M 10-K · filed 2020-03-02 |
| 2017-12-31 | $178.39M 10-K · filed 2019-03-05 |
| 2016-12-31 | $226.80M 10-K · filed 2018-03-01 |
| 2015-12-31 | $207.77M 10-K · filed 2017-02-16 |
| 2014-12-31 | $158.57M 10-K · filed 2016-02-24 |
| 2013-12-31 | $148.60M 10-K · filed 2015-02-26 |
| 2012-12-31 | $122.34M 10-K · filed 2014-03-03 |
| 2011-12-31 | $74.79M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |